bell potters no 1 biotech, page-35

Performace analysis of the Analyst in question. Had an investor acquired shares at the time of recommendation through to now. The investor on all recommendaions was in the money, and had an opportunity to profit, whilst the target price was exceeded on 2 recommendations. The comparission to prices today is predicated by the investors appetite for risk.

feb target now high
ADO $0.08 $0.13 0.057 $0.105
BIT $0.12 $0.35 0.095 $0.190
HIN $2.46 $3.40 2.48 $2.800
MSB $5.51 $7.00 6.39 $10.040
PBT $0.14 $1.10 0.17 $0.380
POH $0.15 $0.40 0.13 $0.250
PRR $0.25 $0.60 0.15 $0.420
QRX $1.29 $2.10 0.69 $2.500
RVA $1.29 $2.10 0.555 $1.380
SPL $0.98 $1.90 1.49 $1.880

I have posted this, to provide a balanced view point on the statistics provided earilier.

I hold continue to hold, however it is with eyes wide open to the up and downside. Listening twice as hard, and talking half as much to all.

In my opinion and upon my analysis NEU is a buy, and hold. DYOR research and respect those who both agree and disagree wih an opinion formed.